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SUMMARY 
The general feasibility of chimerization of monoclonal antibodies (mAbs) has already been shown for a large number of 
them. In order to evaluate in vitro parameters relevant to immunosuppressive therapy, we have chimerized and synthesized 
two anti-CD4 mAbs recognizing two different epitopes on the human T-lymphocyte antigen, CD4. The chimerized mAbs 
are produced at levels corresponding to those of the original hybridoma cell lines. With respect to activation of human 
complement, the individual Abs are negative; however, when used in combination, complement activation was performed. 
When applied in combination, they were found to modulate the CD4 antigen, whereas the individual mAb do not display 
this property. Individually they mediate an up to 60% inhibition of the mixed lymphocyte reaction (MLR). However, by 
combination of an anti-CD4 mAb with one directed against the a-chain of the human IL2 receptor, nearly 100% inhibi- 
tion of the MLR was achieved, even with reduced dosage of the mAbs. Our data suggest hat the combination of an anti-CD4 
mAb and an anti-IL2Rcc chain mAb is more effective with respect to immunosuppression than each mAb by itself, indi- 
cating that this mAb cocktail could be a new strategy for immunosuppressive therapy. 
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heavy chain of Ab; Ig, immunoglobulin; IL2, interleukin 2; ILZR, IL2 
receptor; IL2Ra, c( chain of ILZR; J, joining region; kb, kilobase or 
1000 bp; L, light chain of Ab; mAb, monoclonal Ab; MES, morpholino- 
ethanol-sulfonic acid; MLR, mixed lymphocyte reaction; nt, nucleotide(s); 
PBL, peripheral blood lymphocytes; PBS, phosphate-buffered saline 
(0.15 M NaCl/lOmM Na.phosphate pH 7.5); PCR, polymerase chain 
reaction; RPMI, Roswell Park Memorial Institute (medium); V, gene 
(DNA) encoding V; VDJ, variable region of rearranged H chain; V,, 
variable region of heavy chain; VJ, variable region of rearranged L chain: 
V L1 variable region of light chain. 
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INTRODUCTION 
Antibodies that recognize antigens on the surface of 
human lymphocytes have been used as immunosuppressive 
agents for more than 20 years. Since the development of 
techniques to produce mAb (Kbhler and Milstein, 1975) 
(a) 
1 
ATGATGTCCTCTGCTCAGTTCCTTGGTCTCCTGTTGCTCTGTTTTCMGGTACCAGATGT 
MetMetSerrSerAlaGlnPheLeuGlyLeuLeuLeuLeuCysPheGlnGlyThrArgCys 
-20 
61 
GATATCCAGATGACACAGACTATATCCTCCCTCTCTGCCTAGTCA~C 
AspIleGlnMetThrGlnThrIleSerSerLe"SerAlaSerLe"GlyASpArgValTh~ 
1 20 
121 
ATCAGTTGCAGGGCAAGTCAGGACATTAACARTTATTATTT~GCTGGTATCAGCAG~CCA 
IleSerCysArqAlaSerGlnAs~IleAsnAsnTvrLeuSerTrpTyrGl~GlnLysPrO 
CDRl 40 
181 
GATGGAACTGTTAAACTCCTGATCTACTACACATCAAGATTACATTCAGGAGTCCCAT~A 
AspGlyThrValLysLeuLeuIleTyrTyrThrSerArqLeuH~sSerGlyValProSe~ 
CDR2 60 
241 
AGGTTCAGTGGCAGTGGGTCTGGMCAGATTATTCA 
ArgPheSerGlySerGlySerGlyThrAspTyrSerLeuThrIleThrASnLeuGl"Gln 
80 
301 
GAAGATGTTGCCACTTACTTTTGCCMCAGGGT~TACGCTTCCGTACACGTTCGGAGGG 
GluAspValAlaThrTyrPheCysGlnGlnGlvAsnThrLe"ProT~rThrPheGlyGly 
CDR3 100 
361 
GGGACCAAGCTGGAAAT& 
GlyThrLysLeuGluIleLys 
107 
(cl 
1 
ATGGAGACAGACACAATCCTGCTATGGGTGCTGCTGCTCTGGGTTCCAGGCTCCACTGGT 
MetGluThrAspThrIleLe"Le"TrpValLeuLeuLeuTrpValProGlySerThrGly 
-20 
61 
GACATTGTGCTGACCCAATCTCCAGCTTCTTTGCCTATGTCTCTAGGGCAGAGGGCCA~C 
AspIleValLeuThrGlnSerProAlaSerLeuProMetSerLeuGlyGl~rgAlaThr 
1 20 
121 
ATCTCCTGCAAGGCCAGCCATCTTGATTATGATGGTGATAGTTATATG~CTGGTAC 
IleSerCysL~sAlaSerGlnSerLe"As~TvrAsuGlvAs~SerT~rMetAS~TrpTyr 
CDRl 40 
181 
CAACAGAAACCAGGACAGCCACCCAAACTCCTCCTCATCTATGCTGCATCC~TCTAG~TCT 
GlnGlnLy~Pr~GlyGlnProProLysLe"Le"IleTyrAlaAlaSerAS~Le"Gl"Ser 
CDR2 60 
241 
GGGATCCCAGCCAGATTTAGTGGCAGTGGGTCCGGGACAGACTTCACCCTC~CATCCAT 
GlyIleProAlaArgPheSerGlySerGlySerGlyThrAspPheThrLeuAsnIleHis 
80 
301 
CCTGTGGAGGAGGAGGATGCTGCAACCTATTACTGTCAGCG 
ProValGluGluGl"AspAlaAlaThrTyrTyrCysGlnGlnSerSerGl"AS~PrOPrO 
CDR3 100 
361 
ACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA 
~PheGlyGlyGlyThrLysLeuGluIleLys 
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that recognize a variety of antigens on the lymphocyte sur- 
face, mAbs are clinically applied for the diagnosis and 
ther-apy of an array of human disorders. Possible targets 
for immune intervention focus on two antigens expressed 
by T lymphocytes. CD4 is only expressed by a subset of T 
lymphocytes. This phenotype is usually, but not exclusively, 
(b) 
1 
ATGGCTTGGGTGTGGACCTTGCTTTTCCTGATGGCAGCTGCCC-GTATCC~GCACAG 
MetAlaTrpValTrpThrLeuLeuPheLeuMetAlaAlaAlaGlnSerIleGlnAlaGln 
-19 1 
61 
ATCCAGTTGGTGCAGTCTGGACCTGAGCTGAAGACGCCTGGATCTCC 
IleGlnLe"ValGlnSerGlyPrOGluLysThrProGlyGluThrValLysIleSer 
21 
121 
TGCMGGCTTCTGGTTATACCTTCACAGACTATTCAATACGCTCCA 
CySLysAlaSerGlyTyrThrPheThrAsDTyrSerIleHisTrpValLysGlnAlaPro 
CDRl 41 
181 
GGGAAGGATTTAAAGTGGATGGGCTGGATAAACACTGAGAGACTGGTGAGCC~CATATGCA 
GlyLysAspLeuLysTrpMetGlyTruIleAsnThrGluThrGlvGl"ProThrT~rAla 
CDR2 61 
241 
GATGACTTCACGGGACGGTTTGCCTTCTCTTTGGAAACCTCTGCCAGCACTGCCTATTTG 
AspAsDPheThrGlyArgPheAlaPheSerLeuGluThrSerAlaSerThrAlaTyrLe" 
81 
301 
CAGATCAACAACCTCAAAAATGAGGACACGTCTACATATTTCTGTGCTATTCATTACTAC 
GlnIleASnASnLeuLySASnGluAspThrSerThrTyrPheCysAlaIleHisTvrTyr 
101 
361 
GCCTACGGGGATCCTTTGGACTACTGGGGTCAAGGAACCTTCACCGTCTCCTCA 
AlaTyrGlyAsuProLeuASuTvrTrpGlyGlnGlyThrSerValThrValSe~Se~ 
CDR3 120 
(d) 
1 
ATGGAATGGAGGATCTTTCTCTTCATCCTGTCAGGAACTGGTT 
MetGluTrpArgIlePheLeuPheIleLeuSerGlyThrAlaGlyValHisSerGlnVal 
-18 1 
61 
CACCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGCCTTCAGTG~GATGTCCT~C 
HisLeuGlnGlnSerGlyProGl"Le"ValLysProGlyProSerValLysMetSerCys 
22 
121 
AAGGCTTCTGGATACACATTCACTGACTATGTTGTAAGTTCTGGA 
LysAlaSerGlyTyrThrPheThrAsDTvrValValSerTrpMetGlnGlnArgThrGly 
CDRl 42 
181 
CAGGTCCTTGAGTGGATTGGAGAGATTTATCCTGGAAGTG 
GlnValLeuGluTrpIleGlyGluIleTyrProGlvSerGlvSerAlaT~rT~rAsnGlu 
CDR2 62 
241 
AAATTCAAGGGCAAGGCCATACTGACTGCAGAC-TCCTCCAGCACAGCCTACATGGAG 
LysPheLvsG1yLySAlaIleLe"ThrAlaAspLysSerSerSerThrAlaTyrMetGl" 
R2 
301 
TTCAGCAGCCTGACATCTGAGGACTCTGCGGTCTTTTTCTGTGC~GACGGGGGGATGGT 
PheSerSerLeuThrSerGl"AspSerAlaValPhePheCysAlaArgArqGlVAsuGly 
102 
361 
TCCCTCGGCTTTGCTCACTGGGGCCAAGGGGACTCTGGTCAGTGTCGCTGCA 
SerLeuGlvPheAlaHisTrpGlyGlnGlyThrLe"ValSerValAlaAla 
CDR3 119 
Fig. 1. Sequences of (a) L and (b) H chains of mAb M-T151 and (c) L and (d) H chains of mAb M-T310. The CDR regions (Kabat et al., 1987) are 
underlined. The numbers below the sequence indicate aa positions; 1 indicates the first aa of the mature protein; upstream aa represent the signal se- 
quence. The numbers on the left margin specify the nt positions, with nt = 1 corresponding to the A of the ATG start codon. In (a) the J, region of the 
L chain of mAb M-T15 1 is from Tyr% to Lys”‘, m (b) the J, region of the H chain is from Asp”* to Ser I*‘, in (c) the J, region of the L chain of mAb 
M-T3 10 is from Thr”’ to Lys “I, in (d) the J, region of the H chain is from His”’ to Ala”‘. Methods. RNA was isolated from 1 x 10’ hybridoma cells 
secreting mAbs M-T151 and M-T310 and selected for poly(A)+RNA on oligo(dT) cellulose (Maniatis et al., 1982). cDNA was synthesized with the BRL 
cDNA synthesis kit according to the instructions of the supplier and the sequences determined by the dideoxy method @anger et al., 1977; Weissenhorn 
et al., 1991). 
213 
associated with helper/inducer T cell functions such as 
promoting immunoglobulin production and cytotoxicity. It 
has been shown that mAb targeting of CD4 T cells induced 
profound humoral and cellular immunological unrespon- 
siveness. The experimental findings in the mouse system 
(Cobbold et al., 1984; Miller et al., 1985) have led to clin- 
ical evaluation of anti-CD4 mAbs in the serotherapy of 
diseases (Herzog et al., 1987; Reiter et al., 1991; Reinke 
et al., 1991). The IL2R is a target of considerable interest, 
particularly as it is an activation antigen, composed of an 
inducible a chain (55 kDa) and a p chain (75 kDa), which 
only appears on the surface of T lymphocytes when they are 
activated by antigen or mitogen. Successful therapeutical 
application of an IL2R mAb has been already shown by 
different groups (Kyle et al., 1989; HervC et al., 1990; 
Waldmann, 1991a). 
Since there are limitations to administering non-human 
proteins, efforts to engineer new generations of antibodies 
are underway and are directed towards making the anti- 
bodies more human-like, with the aim of lowering the im- 
munogenicity of these proteins in man and optimizing their 
physiological effector functions and pharmacokinetic char- 
acteristics. One approach to decrease mAb immunogenic- 
ity (Morrison et al., 1984) is the synthesis of chimeric mAb. 
After the demonstration that lymphoid cells can express 
cloned, transfected Ig genes, mouse/human chimeric mAbs 
were generated with specificities directed towards a wide 
range of tumour antigens and T-cell surface molecules. The 
benefits of chimeric mAb for serotherapy in humans are 
widely accepted. 
The aim of this work was to generate chimeric mouse/ 
human antibodies directed against the T-cell antigen CD4. 
Furthermore, the chimeric mAbs M-T310 and M-T151 
were analysed alone and in combination with MAK 179, 
an IL2Rcr chimeric mAb (Kaluza et al., 1991), with respect 
to their physiological effector functions. With the aim of 
possible clinical application, we have evaluated in vitro 
possible synergistic effects between the two anti-CD4 mAb 
M-T310 and M-T151, recognizing two different epitopes 
on the first and second extracellular domains of the T-cell 
surface glycoprotein CD4 (Peterson and Seed, 1988; Sat- 
tentau et al., 1989; Ashkenazi et al., 1990) and combina- 
tions of the two anti-CD4-specific chimeric mAbs with the 
IL2Ra-specific chimeric mAb MAK 179. 
RESULTS AND DISCUSSION 
(a) Cloning and sequence analysis of V region sequences 
The functionally rearranged V, and V, regions of mAbs 
M-T310 and M-T151 have been cloned and subsequently 
fused to human constant region gene segments encoding 
the human yl chain (vector pUHWy1) and human IC chain 
(vector pUHWrc), as described (Weissenhorn et al., 1991). 
The nt and the deduced aa sequences of anti-CD4 mAb V, 
and V, regions are shown in Fig. 1. Both the V, and V, 
sequences of anti-CD4 mAbs M-T310 and M-T151 show 
no significant homology with respect to their nt and aa 
sequences. The V, region genes can be attributed to two 
different VH gene families according to previously defined 
a b c d e f a b c d e f 9 h i j k I 
0.9 kb b 
s+ 41.6 kb 41.6 kb 
0.9 kb, 
Fig. 2. Northern blot analysis of hybridomas and transfectomas secreting murine and chimeric mAb M-T151 and M-T310. Panel A displays the analy- 
sis of K and y transcripts for mAb M-T310: lanes a-c K transcripts of mAb M-T310; a, transfectoma; b, hybridoma; c, recipient cell line Sp2/0. Lanes 
d-f, y transcripts of mAb M-T310. Panel B shows the equivalent analysis for mAb M-T151. The sizes of the detected transcripts are shown in kb. K 
and y transcripts of mAb M-T151: a-f, K transcripts; g-l, y transcripts; a-d, four transfectomas; e, hybridoma; f, Sp2/0, g-j, four transfectomas corre- 
sponding to those in lanes a-d; k, hybridoma; I, Sp2/0. Methods. Total RNA was extracted from 1 x 10’ cells according to the method described by Auffray 
and Rougeon (1980). Ten pg of total RNA was electrophoresed on a 1.2% agarose gel containing 2.2 M formaldehyde and transferred to a nitrocellu- 
lose membrane (Amersham, Braunschweig, Germany) by standard procedures (Maniatis et al., 1982). The blots were hybridized with V-specific probes. 
For detection of K mRNA a 274-bp EcoRV-Not1 fragment was used for M-T151; for M-T310 a 248-bp KpnI-Not1 fragment was used as a probe. The 
y transcripts were detected with the following probes: a 767-bp Sty1 fragment for mAb M-T310 and a 367-bp BarnHI-BglII fragment for M-T151. Ra- 
dioactive probes were obtained by labelling the fragments with [ c(-3ZP]dCTP using the random primed DNA-labelling kit supplied by Boehringer Mannheim. 
Then 2 x lo6 cpm per labelled fragment were used for hybridization, which was performed as described in Maniatis et al. (1982). 
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V, gene families. V gene families comprise groups of re- 
lated V genes that in general share greater than 80% se- 
quence similarity (Brodeur and Riblet, 1984; Winter et al., 
1985; Kabat et al., 1987). The V, region gene segment of 
mAb M-T3 10 is a member of the 5558 gene family, and the 
V, region of mAb M-T15 1 belongs to the VGam gene 
family. The V, regions display different D region segments 
which have been rearranged either to 53 or to 54. The 
heterogeneous nature of the ‘D’ sequences makes the pre- 
cise determination of V,-D and D-J, boundaries impos- 
sible. Although none of these somatic D regions corre- 
sponds exactly to identified germline D segments 
(Kurosawa and Tonegawa, 1982), they all show regions of 
homology flanked by relatively G-rich sequences (N se- 
quences) which have previously been proposed to be in- 
serted during V,-D and D-J, joining events (Alt and Bal- 
timore, 1982). Similar results were obtained for the VIC 
sequences. M-T3 10 Vlc is a member of the V1c21 subgroup 
and Vlc M-T151 of the VlclO subgroup (Kabat et al., 1987; 
Kofler et al., 1989; Strohal et al., 1989). VK M-T310 is 
rearranged to Jl and VK. M-T151, to 52. This diversity in 
sequence correlates with their different CD4 antigen bind- 
ing pattern. Both mAbs recognize different epitopes on the 
CD4 molecule as indicated by cross-blocking experiments 
(data not shown), and they map to different antigenic re- 
gions, as shown by mutational analysis of the CD4 mole- 
cule (Peterson and Seed, 1988; Sattentau et al., 1989; Ash- 
kenazi et al., 1990). 
(b) Synthesis of chimeric mAb M-T151 and M-T310 in 
transfectomas 
Genomic VJ and VDJ regions of mAbs M-T151 and 
M-T3 10 were isolated by the PCR reaction, fused to human 
IC and yl constant regions, transfected into Sp2/0 cells and 
stable transformants isolated by G418 selection. Details 
are described in Weissenhorn et al. (1991). Fig. 2 reveals 
that transfectants with steady state levels of K- and yl- 
specific transcripts corresponding in abundance to those of 
the original hybridoma cells could be isolated after screen- 
ing about 200 transfectants for each chimeric mAb. This 
holds true with the exception of the transfectant shown in 
Fig. 2B, lanes d and j. With the K--specific V region probe, 
slight cross-hybridisation to an endogeneous IC message in 
the recipient cell line Sp2/0 was observed (Fig. 2A, lane c). 
This message contains a premature stop codon and does 
not mediate synthesis of a secreted, truncated protein (Ca- 
billy and Riggs, 1985). Synthesis of murine and chimeric 
mAb corresponds to 15-20 pg/ml/106 cells/24 h. The iso- 
lated VJ and VDJ regions contain the authentic introns in 
the signal sequences of L and H chains. Expression of the 
chimeric genes is mediated by a tandem combination of a 
H chain promoter/enhancer element (Weissenhorn et al., 
1991). The result indicates that transfectomas with expres- 
sion levels of chimeric mAb corresponding to those of the 
original hybridoma can be established with this experimen- 
tal design without the need to amplify transfected genes. 
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Fig. 3. Activation of human complement by anti-CD4 mAb. Deposition 
of complement components C3c, C4 and C5 is shown as total fluores- 
cence mean channel after detection by C3-, C4- and CS-specific FITC- 
conjugated antisera in a FACscan analysis; a, m M-T151 (IgG,,); b, m 
M-T310 (IgGl); e,m M-TlSl+m M-T310; d,chim M-T151 (IgGl); 
e, chim M-T310 (IgGl); f, chim M-T15l+chim M-T310. Open bars re- 
present C3c, filled bars C4 and stippled bars C5. Methods. Hybridomas 
and transfectomas were fermented in a lo-liter reactor in suspension 
culture with 5% FCS. After concentration of the eluate to 700 ml, the *J 
globulin fraction was precipitated by adjusting the supematant to 2 M 
(NH,),SO, pH 7. After dialysis against 10 mM MES buffer pH 5.8, the 
fraction was applied to an S-Sepharose column (Pharmacia) equilibrated 
with the same buffer at 4”C, eluted with a linear NaCl gradient (0. l- 
0.25 M pH 5.8), and fractions containing mAbs were pooled. The material 
was adjusted to 1 M (NH,),SO, pH 9, applied to a Protein A Sepharose 
column (Pharmacia) equilibrated with the same buffer and eluted with 
0.1 M Na,.citrate pH 3.4. After dialysis against PBS buffer pH 7.5 and 
ultrafiltration, contaminating bovine IgG was removed by adsorption to 
Spherosil conjugated with sheep anti-bovine IgG. For the complement 
activation experiments, PBL from EDTA-blood of healthy adults were 
isolated by Ficoll-Hypaque density centrifugation. Then 1 x lo5 PBL were 
incubated with 50 ~1 of purified mAb (10 pg/ml of each mAb) for 30 min 
on ice. After washing twice with ice-cold PBS, 50 ~1 of fresh human serum 
was added to the cells and incubated for 20 min at 37°C. For the nega- 
tive control, mAb-targeted cells were incubated with heat-inactivated 
serum. The cells were washed twice with ice-cold PBS and subjected to 
complement component-specific antisera and incubated on ice for 20 min 
(for detection of C3c a rabbit anti-C3c, for C4 a rabbit anti-C4 FITC- 
conjugated serum and for C5 a rabbit anti-C5 serum was used; all from 
Dakopatts). After washing cells twice with PBS, the anti-C3c and anti- 
C5 targeted cells were further incubated with goat anti-rabbit Ig FITC- 
conjugated serum (Dianova) for 20 min on ice, washed twice with PBS 
and fixed with 1% paraformaldehyde. The fluorescence intensity was 
quantified by FACscan analysis as fluorescence mean channel of living 
CD4’ cells on a log scale. The value of the mean channel was obtained 
by subtraction of the value of the mean channel of the negative control 
(incubation of CD4-mAb-targeted T cells with heat-inactivated serum and 
detection of cells with complement-specific antisera) from total mean 
channel of positive experiments. 
(c) Complement activation 
As the aim of targeted mAb therapy is either modulation 
of the CD4 molecule (Lifson and Engleman, 1989) or elim- 
ination of reactive T cells, it was important to evaluate the 
complement activation properties of our mAbs. Compared 
with other human Ig subclasses, the greatest effectiveness 
with respect to physiological effector functions has been 
described for the IgGl isotype (Brtiggemann et al., 1987; 
Riechmann et al., 1988). We therefore selected the human 
IgG 1 isotype for chimerization of the anti-CD4 mAbs. The 
activation of complement was assayed by determination of 
the ability of the mAbs to induce deposition of components 
of the complement cascade on the surface of CD4’ PBL. 
The results show that murine M-T151 (IgG,,) activates 
human complement weakly (Fig. 3a), whereas murine 
M-T310 (IgGl) is negative with respect to this property 
(Fig. 3b). The combination of these murine anti-CD4 mAbs 
results in a dramatic enhancement of activation of human 
complement (Fig. 3~). The chimeric mAbs M-T15 1 (IgGl) 
and M-T3 10 (IgGl) do not display human complement- 
activating properties (Fig. 3d,e) by themselves; however, a 
combination of these mAbs results in complement activa- 
tion stronger than the activation induced by a combination 
of the murine mAb (Fig. 3f). As a negative control, mAb- 
targeted cells have been incubated with heat-inactivated 
serum. Consistently, only background levels of fluorescence 
intensity have been observed (data not shown). Unfortu- 
nately, a lytic mAb pair was not available for our studies. 
Synergy with respect to complement activation for pairs of 
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mAbs has also been shown by Bindon et al. (1985) and 
Hughes-Jones et al. (1983). 
(d) Immunomodulation by chimeric anti-CD4 mAbs 
To determine the possible role of modulation of CD4+ 
cells rather than elimination of these cells, the effect of 
anti-CD4 mAbs on whole blood cells was determined. 
Fig. 4 shows the result of these experiments. The blood of 
both donor A and donor B did not show any effect when 
coculturing the whole blood with only one chimeric anti- 
CD4 mAb alone. The amount of CD4’ cells from time 
point 0 until 48 h, differentiating into total CD4, high- 
expressing and low-expressing cells, resulted in the same 
graphs in the control samples as well as in the samples 
containing either the anti-CD4 mAb M-T3 10 or M-T15 1. 
There is no significant decrease of CD4+ cells induced by 
the chimeric anti-CD4 mAb. By adding both anti-CD4 
mAbs, M-T310 and M-T151, the CD4 level changes from 
time point 0 to 48 h. Samples of both blood donors show 
a 90 y0 (A) and 70 y0 (B) reduction of high-expressing CD4 
cells and an increase of low-expressing CD4 cells (by a 
factor of 5). The reduction of high-expressing cells corre- 
lates with the increase of low-expressing cells. Summing up 
the amounts of high- and low-expressing CD4 cells at time 
point 48 h leaves the total amount of all CD4+ cells un- 
changed. Therefore, we conclude from these experiments 
that our chimeric anti-CD4 mAbs induce modulation of the 
CD4 antigen rather than elimination of CD4-expressing 
cells. 
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Fig. 4. Immunomodulation by chimeric CD4 mAbs. Reduction of total and high CD4-expressing cells as well as increase of low CD4-expressing cells 
are shown by the different graphs after incubation of whole blood cells with chimeric mAbs or combinations thereof. In graphs A and B blood of two 
different donors was analysed. Total, high and low CD4-expressing cells were determined at the beginning of the experiment and at 24 and 48 h after 
incubation with the mAbs, respectively. Filled squares represent total CD4 cells, filled triangles high CD4-expressing cells, and open circles display low 
CD4-expressing cells. Methods. 100 ~1 of whole heparin-treated blood was cocultured with chimeric anti-CD4 mAb (100 ng/ml) at 37°C in flat-bottom 
microtiter plates in duplicates. At time points 0, 24 and 48 h, the amount of CD4’ cells was determined by FACscan analysis with the FITC-conjugated 
mAb 0KT4 (Ortho). CD4+ cells have been determined in total as well as grouped into low and high CD4-expressing cells according to their fluores- 
cence intensity. For flow cytometry 10’ FITC-labelled CLL cells (plus 10 ng/ml propidium bromide) were added to each sample as the standard cell 
population. Total CD4+ cells were determined relative to the amount of detected standard cells. There is no cross-blocking of the chimeric Abs by OKT4. 
276 
TABLE I TABLE II 
Dose-dependent inhibition of MLR by individual chimer& mAbs Inhibition of MLR by selected combinations of mAbs 
mAb concentrations 
(ngiml) 
Inhibition of MLRa (%) 
MAK 179 M-T310 M-T151 
mAb concentrations (ng/ml)” 
M-T3 10 M-T151 MAK 179 
Inhibition of 
MLR (%) 
MAK 215 
1 4 9 5 
3 11 18 2 
10 28 26 24 
30 48 57 52 
100 58 58 54 
300 61 61 67 
1000 61 68 67 
30000 61 70 70 
a Methods. Human PBL were isolated from a single healthy donor by 
elutriation (Red Cross, Munich, FRG) followed by discontinuous gradi- 
ent centrifugation with lymphocyte separation medium (Boehringer Mann- 
heim, Germany). Cells at the interphase were collected and washed twice 
with RPM1 1640 (supplemented with 10% fetal calf serum/tmM 
glutamine/l % BME vit~ins~lO0 pg penicillin/IO0 pg streptomycin, all 
per ml, from Boehringer M~nheim, Germany. Then lo7 stimulator cells 
(human lymphocyte cell line RPM1 1788, ATCC CCL 156) were treated 
for 45 min at 37°C and 5% CO2 in a volume of 1 ml with 50 pg mitomycin 
C/ml. After centrifugation, cells were washed twice with RPM1 1640 and 
adjusted to a cell titer of lo6 cells/ml. MLR was performed by co-culturing 
10’ PBLjlOO ~1 with the same amount of stimulator cells in flat-bottom 
microtiter plates (Nunc). The mAbs were added either alone or in com- 
bination in a 20-~1 volume to give the final concentration as indicated in 
the table. The allogeneic response was assayed on day four by pulsing the 
cells with 0.5 @Ci [‘HI-thymidine (25 Ci/mM, Amersham Buchler). After 
18 h the cultures were terminated by harvesting the cells on glassfiber 
filters, and the amount of radioactivity incorporated into the cellular DNA 
was determined with the filter counting system INB-384 (Inotech, Wohlen, 
Switzerland). 
All assays were done in triplicates and the results expressed as: 
l- 
( 
CPmexpsrilnent - cPmbackground 
cPmpoalllve cOntrOl - wmbackground > 
x 100 = % inhibition in MLR 
where cpm = counts per min; cpm,,p,,i,,,,,i is the MLR response with 
mAbs; cpmix,sili,se COntrd is the MLR response without mAbs; 
cpmback+roUnd represents the spontaneous proliferation of responder cells. 
Anti-CD4 mAb has the potential to modulate the func- 
tion of CD4” cells either by delivering an ~activating sig- 
nal (Rosoff et al., 1987) or by inhibiting the association of 
the CD4 molecule with the T cell receptor-CD3 complex or 
by blocking its interaction with MHC class II molecules on 
cooperating cells. In vivo experiments have shown that the 
immunosuppressive effect and the induction of tolerance by 
anti-CD4 mAbs does not entirely depend on cell depletion 
{Benjamin et al., 1988; Alters et al., 1990; Cobbold et al., 
1990; Qin et al., 1990). Furthermore it has been shown that 
Fab fragments of an anti-CD4 mAb mediate immuno- 
suppression (Carteron et al., 1988). Qin et al. (1987) have 
demonstrated an improved clearance of cells in vivo and 
tolerance induction, using synergistic pairs of anti-CD4 
mAbs. 
1 6 
10 38 
100 59 
1 
10 
100 
t 
I 
10 
100 
0 
29 
57 
0 
23 
53 
10000 5 
1 100 65 
IO 100 64 
100 100 60 
100 1 58 
100 10 58 
100 100 60 
100 1 59 
100 10 69 
100 100 92 
100 1 58 
100 10 64 
100 100 96 
100 10000 40 
100 10000 45 
a The mAbs used are chimeric (IgGl), with the exception of MAK215. 
This mAb (IgG2J is directed against the r chain of the IL2R and does 
not compete with IL2 binding (unpublished observations). 
For methods see Table I. 
(e) Inhibition of MLR 
When lymphocytes from two genetically different indi- 
viduals of a species are mixed in cell culture medium, the 
T cells of each indi~dual respond to the MHC antigens of 
the other by d~erentiation and proliferation. This process 
is called mixed lymphocyte reaction (MLR). Allogeneic 
antigens presented on accessory cells stimulate precursor 
cells, and the effector cells secrete IL2 and other lympho- 
kines that cause maturation of effector T cells. Since these 
mechanisms are responsible for allograft rejection, it is of 
great interest to suppress T-cell reactivity in allograft pa- 
tients. In the present study we demonstrate that each chi- 
merit anti-CD4 mAb by itself inhibits markedly MLR. This 
can also be achieved by the anti-IL2Ra mAb MAK179. As 
shown in Table I, a dose-dependent inhibition of the MLR 
up to a concentration of 300 ngjml can be obtained with 
these three mAbs. The maximum inhibition of MLR is 
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about 60-70 %. An increase of the mAb concentration to 
30 pg/ml did not result in any further increase in inhibition. 
Probably, the proliferation of lymphocytes is supported by 
additional signals, besides those mediated by CD4 and 
IL2R. 
For clinical applications it is important to accomplish a 
high degree of suppression of T-cell proliferation. In Table 
II we show that a combination of the chimeric anti-CD4 
mAbs M-T310 and M-T151 did not lead to a marked in- 
crease in MLR inhibition; however, either of the anti-CD4 
mAbs (M-T310 or M-T151) in combination with the anti- 
IL2Ra mAb MAK 179 mediates an almost 100% inhibi- 
tion of MLR, using each mAb in a concentration of 100 ng/ 
ml. The combination of each anti-CD4 mAb and another 
anti-ILfRa mAb M215, which does not compete with 
binding of IL2 to its receptor (unpublished observations), 
did not show any synergistic effect, even when used at a 
concentration of 10 pg/ml (data not shown). In addition, 
even at reduced concentrations (10 ng/ml of each mAb) the 
combination of either one of the two anti-CD4 mAbs and 
the anti-IL2Ra mAb MAK 179 resulted in almost 50% 
inhibition of the MLR. 
These data show that an inhibition of the MLR can be 
achieved very effectively by the combined administration of 
one of the two anti-CD4 mAbs and the anti-ILfRa mAb 
MAK 179. During treatment of autoimmune diseases and 
following organ transplantation, mAbs are administered in 
doses ranging from 20 to 50 mg per day. By using an anti- 
CD4/IL2Ra mAb cocktail, we assume that the same im- 
munosuppressive effect might be obtained by a 5-10 times 
lower dose than when using either one alone. 
(f) Conclusions 
(I) We were able to establish transfectomas with Ig- 
specific mRNA steady state levels comparable to those of 
the original hybridoma cell lines with our cloning/ 
expression system. The mRNA steady state levels corre- 
lated with the secretion of reconstituted mAb into the cul- 
ture supernatants. 
(2) Selective T-cell-targeted therapy is an attractive al- 
ternative to non-specific immunosuppressive drugs in the 
treatment of graft rejections as well as autoimmune disor- 
ders. The chimerization of mAbs reduces their immunoge- 
nicity (Brtiggemann et al., 1989) for serotherapy in humans, 
it enhances the serum half-life and improves physiological 
effector functions (reviewed by Waldmann, 1991b). 
(3) Chimeric mAbs M-T151 and M-T310 seem to be 
suitable for the therapy of autoimmune diseases. The mu- 
rine mAb M-T 15 1 has been already used successfully in a 
limited trial (Herzog et al., 1987). Complement activation 
and antigen modulation are only performed by a combina- 
tion of the chimeric anti-CD4 mAb; the individual mAbs 
do not display these properties. Therefore, we suggest that 
a combination of both chimeric mAbs is more effective than 
the administration of a single mAb. 
(4) For the treatment of graft rejections, a combination 
of an anti-IL2Rcr-chain mAb and an anti-CD4 mAb seems 
to be a very effective combination, as T-cell proliferation 
can be almost completely suppressed. 
(5) Our study shows that combinations of mAbs are 
more effective than single mAbs with respect to several 
properties (complement activation, CD4 modulation, inhi- 
bition of MLR). Cocktails of mAbs containing anti-CD4 
mAbs and/or IL2Ra mAbs and also mAbs directed to 
other T-cell accessory molecules should provide new tools 
for immunotherapy. 
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